Periostin as a Biomarker for Prostate Cancer
Author Information
Author(s): Sun Chuanyu, Song Chao, Ma Zhicheng, Xu Ke, Zhang Yang, Jin Hong, Tong Shijun, Ding Weihong, Xia Guowei, Ding Qiang
Primary Institution: Huashan Hospital, Fudan University
Hypothesis
The study aims to identify biomarkers of prostate cancer using proteomics analysis.
Conclusion
The study suggests that periostin is significantly up-regulated in prostate cancer compared to benign prostate hyperplasia, indicating its potential as a biomarker.
Supporting Evidence
- 760 proteins were identified from 13787 distinct peptides.
- 20 proteins were significantly up-regulated and 26 were down-regulated in prostate cancer compared to benign prostate hyperplasia.
- Immunohistochemical staining showed high expression of periostin in the stroma of prostate cancer tissues.
Takeaway
This study found that a protein called periostin is much higher in prostate cancer than in benign conditions, which could help doctors diagnose and treat the disease better.
Methodology
The study used iTRAQ-proteomics analysis combined with two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) to analyze prostate biopsy samples.
Potential Biases
Potential biases may arise from the selection of biopsy samples and the specific population studied.
Limitations
The study focused on a specific population and may not be generalizable to all demographics.
Participant Demographics
Participants included 20 patients with benign prostate hyperplasia, 20 with prostate cancer, and 10 with benign hyperplasia with local prostatic intraepithelial neoplasm.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website